{"id":"matching-placebo-sc","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Matching placebos are inert formulations designed to be indistinguishable from the active drug in appearance, administration route, and frequency. They serve as the control arm in blinded clinical trials to isolate the true therapeutic effect of the active agent from placebo response and other trial-related factors.","oneSentence":"This is a placebo control formulation used in clinical trials to match the subcutaneous administration route of an active investigational drug.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:16.180Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06972446","phase":"PHASE2","title":"A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-20","conditions":"Rheumatoid Arthritis","enrollment":180},{"nctId":"NCT07037771","phase":"PHASE3","title":"A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)","status":"RECRUITING","sponsor":"Arrowhead Pharmaceuticals","startDate":"2025-06-17","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":60},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT06963827","phase":"PHASE3","title":"A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-07-15","conditions":"Kidney Disease","enrollment":347},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07363694","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-11","conditions":"Moderate to Severe Chronic Obstructive Pulmonary Disease","enrollment":1156},{"nctId":"NCT07133633","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-09-26","conditions":"Radiographic Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT07284901","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2026-01-12","conditions":"Obesity With Diabetes, Overweight With Diabetes","enrollment":1700},{"nctId":"NCT06290141","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-08-21","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":160},{"nctId":"NCT06980805","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)","status":"RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2025-02-19","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":56},{"nctId":"NCT05403541","phase":"PHASE3","title":"Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2022-06-27","conditions":"Generalized Myasthenia Gravis","enrollment":240},{"nctId":"NCT06339008","phase":"PHASE3","title":"A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-26","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":450},{"nctId":"NCT07276581","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-15","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT04720534","phase":"PHASE2","title":"Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2021-05-31","conditions":"Severe Hypertriglyceridemia","enrollment":229},{"nctId":"NCT06383390","phase":"PHASE3","title":"The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-30","conditions":"Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)","enrollment":10000},{"nctId":"NCT06209177","phase":"PHASE1","title":"Study of ARO-CFB in Adult Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arrowhead Pharmaceuticals","startDate":"2024-04-05","conditions":"IgA Nephropathy","enrollment":49},{"nctId":"NCT05075824","phase":"PHASE2","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-09","conditions":"Sickle Cell Disease","enrollment":90},{"nctId":"NCT07207954","phase":"PHASE1","title":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Lifordi Immunotherapeutics, Inc.","startDate":"2025-10-06","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT06430801","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-05","conditions":"Crohn's Disease","enrollment":1200},{"nctId":"NCT05352919","phase":"PHASE3","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Biogen","startDate":"2022-06-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":864},{"nctId":"NCT06589986","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-09-17","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":400},{"nctId":"NCT07481734","phase":"PHASE2","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis","enrollment":120},{"nctId":"NCT06995820","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-06","conditions":"Healthy","enrollment":136},{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT05492500","phase":"PHASE2","title":"A Study of Ponsegromab in People With Heart Failure","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-09-26","conditions":"Heart Failure","enrollment":455},{"nctId":"NCT05693935","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-24","conditions":"Schizophrenia","enrollment":675},{"nctId":"NCT06819891","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-12","conditions":"Moderately to Severely Active Crohns Disease","enrollment":425},{"nctId":"NCT05528510","phase":"PHASE3","title":"A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-13","conditions":"Colitis, Ulcerative","enrollment":418},{"nctId":"NCT06052059","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-10-25","conditions":"Ulcerative Colitis","enrollment":1020},{"nctId":"NCT05115110","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-02","conditions":"Spinal Muscular Atrophy (SMA)","enrollment":259},{"nctId":"NCT05797610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-08-08","conditions":"Primary IgA Nephropathy","enrollment":428},{"nctId":"NCT05271409","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-08-30","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","enrollment":152},{"nctId":"NCT07284979","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2025-12-30","conditions":"Obesity","enrollment":1200},{"nctId":"NCT07090655","phase":"EARLY_PHASE1","title":"A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Climb Bio, Inc.","startDate":"2025-08-11","conditions":"Healthy Volunteers","enrollment":38},{"nctId":"NCT04882098","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Active Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-06-17","conditions":"Arthritis, Psoriatic","enrollment":1054},{"nctId":"NCT04929210","phase":"PHASE4","title":"A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-30","conditions":"Arthritis, Psoriatic","enrollment":411},{"nctId":"NCT05347095","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen-Cilag Ltd.","startDate":"2022-09-27","conditions":"Fistulizing Crohns Disease, Perianal Crohns Disease","enrollment":288},{"nctId":"NCT07137585","phase":"PHASE1","title":"A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-09-30","conditions":"Type 2 Diabetes Mellitus, Obesity, Overweight","enrollment":30},{"nctId":"NCT04033445","phase":"PHASE2, PHASE3","title":"A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-26","conditions":"Ulcerative Colitis","enrollment":1064},{"nctId":"NCT04936308","phase":"PHASE3","title":"Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Arthritis, Psoriatic","enrollment":453},{"nctId":"NCT03953300","phase":"PHASE4","title":"Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-08","conditions":"Asthma","enrollment":75},{"nctId":"NCT07096193","phase":"PHASE1, PHASE2","title":"Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-07-31","conditions":"Chronic Hepatitis Delta","enrollment":107},{"nctId":"NCT06015737","phase":"PHASE3","title":"A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-29","conditions":"Cutaneous Lupus Erythematosus","enrollment":302},{"nctId":"NCT06834347","phase":"PHASE3","title":"A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-12","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":210},{"nctId":"NCT06834360","phase":"PHASE3","title":"A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-06","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":210},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT07458269","phase":"PHASE2","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Kailera","startDate":"2026-03","conditions":"Obesity","enrollment":250},{"nctId":"NCT06323928","phase":"PHASE2","title":"A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lundbeck A/S","startDate":"2024-04-01","conditions":"Migraine","enrollment":874},{"nctId":"NCT06722235","phase":"PHASE3","title":"A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-02-27","conditions":"Immune Thrombocytopenic Purpura (ITP)","enrollment":171},{"nctId":"NCT07137598","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-12-05","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT05692180","phase":"PHASE3","title":"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-04-05","conditions":"Asthma","enrollment":200},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT06787586","phase":"PHASE1","title":"Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Attovia Therapeutics Inc","startDate":"2025-01-14","conditions":"Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema","enrollment":108},{"nctId":"NCT06819878","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-03-17","conditions":"Moderately to Severely Active Crohns Disease","enrollment":600},{"nctId":"NCT06588855","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-12-11","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":350},{"nctId":"NCT06747468","phase":"PHASE3","title":"Avexitide for Treatment of Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2025-04-29","conditions":"Post Bariatric Hypoglycemia","enrollment":75},{"nctId":"NCT06878261","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":990},{"nctId":"NCT06883305","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-18","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":990},{"nctId":"NCT04951622","phase":"PHASE3","title":"A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-07-15","conditions":"Myasthenia Gravis","enrollment":199},{"nctId":"NCT06851858","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-12","conditions":"Endocrinology, Diabetes, Type II, Obesity","enrollment":69},{"nctId":"NCT07172022","phase":"PHASE2","title":"A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-03-16","conditions":"Antiphospholipid Syndrome","enrollment":""},{"nctId":"NCT07284875","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2025-12-18","conditions":"Obesity, Overweight","enrollment":1800},{"nctId":"NCT04896008","phase":"PHASE3","title":"A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2021-12-01","conditions":"Pulmonary Arterial Hypertension","enrollment":173},{"nctId":"NCT07172867","phase":"PHASE2","title":"A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM","status":"WITHDRAWN","sponsor":"Halia Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":""},{"nctId":"NCT06137183","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2024-05-01","conditions":"Ulcerative Colitis","enrollment":79},{"nctId":"NCT06966479","phase":"PHASE2","title":"A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)","status":"RECRUITING","sponsor":"Upstream Bio Inc.","startDate":"2025-05-21","conditions":"Severe Asthma","enrollment":436},{"nctId":"NCT04998201","phase":"PHASE2","title":"Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2021-09-28","conditions":"Mixed Dyslipidemia","enrollment":353},{"nctId":"NCT07074977","phase":"PHASE2","title":"Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)","status":"RECRUITING","sponsor":"Galderma R&D","startDate":"2025-10-20","conditions":"Chronic Pruritus of Unknown Origin","enrollment":50},{"nctId":"NCT06718101","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-12-19","conditions":"Atopic Dermatitis","enrollment":83},{"nctId":"NCT07176390","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Arthritis, Rheumatoid","enrollment":182},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT07224360","phase":"PHASE2","title":"Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2026-02-02","conditions":"Sickle Cell Disease","enrollment":63},{"nctId":"NCT07248865","phase":"PHASE1","title":"A Phase 1 Study of CLYM116 in Normal Healthy Volunteers","status":"RECRUITING","sponsor":"Climb Bio, Inc.","startDate":"2025-12-02","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT03929601","phase":"PHASE2","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-30","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT04191304","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-20","conditions":"Hypereosinophilic Syndrome","enrollment":134},{"nctId":"NCT07356713","phase":"PHASE1","title":"A Study to Find a Suitable Dose of Exl-111 for Further Research","status":"RECRUITING","sponsor":"Excellergy Inc.","startDate":"2026-01-08","conditions":"Allergic Disease","enrollment":70},{"nctId":"NCT06954428","phase":"PHASE1","title":"Clinical Trial of Intranasal Delivery of NT-301","status":"COMPLETED","sponsor":"Nano PharmaSolutions Australia","startDate":"2025-06-20","conditions":"Tolerability of NT-301 Nasal Spray, Pharmacokinetics of NT-301 Nasal Spray, Safety of NT-301 Nasal Spray","enrollment":49},{"nctId":"NCT06111586","phase":"PHASE2","title":"FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-12-11","conditions":"Type 1 Diabetes Mellitus","enrollment":192},{"nctId":"NCT03157635","phase":"PHASE1, PHASE2","title":"Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2016-11-14","conditions":"Paroxysmal Hemoglobinuria, Nocturnal","enrollment":59},{"nctId":"NCT07375758","phase":"PHASE1, PHASE2","title":"A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2026-02","conditions":"Immunoglobulin A Nephropathy","enrollment":130},{"nctId":"NCT05712200","phase":"PHASE3","title":"Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)","status":"RECRUITING","sponsor":"Anthos Therapeutics, Inc.","startDate":"2022-12-27","conditions":"Atrial Fibrillation (AF)","enrollment":1900},{"nctId":"NCT05552157","phase":"PHASE2, PHASE3","title":"A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-11-22","conditions":"Alzheimers Disease, Dementia, Alzheimers Disease, Familial","enrollment":280},{"nctId":"NCT06280391","phase":"PHASE2","title":"A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2024-02-20","conditions":"Bronchiectasis","enrollment":312},{"nctId":"NCT06965413","phase":"PHASE2","title":"A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-05","conditions":"Obesity, Overweight, Overweight With One Weight Related Comorbidity","enrollment":285},{"nctId":"NCT07032662","phase":"PHASE2","title":"IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Immunovant Sciences GmbH","startDate":"2025-03-18","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":162},{"nctId":"NCT05079919","phase":"PHASE3","title":"A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2021-10-25","conditions":"Severe Hypertriglyceridemia","enrollment":617},{"nctId":"NCT06593600","phase":"PHASE2","title":"Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-11-13","conditions":"Postural Orthostatic Tachycardia Syndrome (POTS)","enrollment":81},{"nctId":"NCT04895241","phase":"PHASE3","title":"A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2021-05-25","conditions":"Lupus Erythematosus, Systemic","enrollment":548},{"nctId":"NCT05610280","phase":"PHASE3","title":"A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2022-11-21","conditions":"Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis","enrollment":1478},{"nctId":"NCT06501586","phase":"PHASE1","title":"Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects","status":"COMPLETED","sponsor":"Suzhou Sanegene Bio Inc.","startDate":"2024-07-31","conditions":"Hypertension,Essential","enrollment":40},{"nctId":"NCT06132841","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-13","conditions":"Healthy Participants","enrollment":104},{"nctId":"NCT05785624","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2023-05-26","conditions":"Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement","enrollment":286},{"nctId":"NCT06880770","phase":"PHASE3","title":"Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis","status":"RECRUITING","sponsor":"Arrowhead Pharmaceuticals","startDate":"2025-04-24","conditions":"Severe Hypertriglyceridemia","enrollment":288},{"nctId":"NCT06143371","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2023-08-21","conditions":"Healthy, Plaque Psoriasis","enrollment":80},{"nctId":"NCT05089084","phase":"PHASE3","title":"Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arrowhead Pharmaceuticals","startDate":"2021-12-14","conditions":"Familial Chylomicronemia","enrollment":75},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT04157348","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-29","conditions":"Eosinophilic Granulomatous Vasculitis","enrollment":140},{"nctId":"NCT04961567","phase":"PHASE3","title":"A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2021-07-16","conditions":"Lupus Erythematosus, Systemic","enrollment":562},{"nctId":"NCT07306585","phase":"PHASE1","title":"The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE","status":"NOT_YET_RECRUITING","sponsor":"HC Biopharma Inc.","startDate":"2025-12-30","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":32},{"nctId":"NCT06103877","phase":"PHASE1","title":"A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-01","conditions":"Healthy Volunteers","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching Placebo SC","genericName":"Matching Placebo SC","companyName":"Immunovant Sciences GmbH","companyId":"immunovant-sciences-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}